newsfilter
← Latest News
GlobeNewswire·

Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504

EQ

Topline Phase 1 proof-of-mechanism data anticipated in Q2 2027 Randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, PK and PD of EQ504 Triggers Milestone Closing of $20 million in